MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$5,914,459
Free Cash flow
-$1,642,129
Unit: Dollar
Positive Cash Flow Breakdown
    • Proceeds from issuance of common...
    • Accounts payable
    • Accrued expenses and other curre...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Issuance costs related to issuan...
    • Purchase of property and equipme...
    • Payment of finance lease
Cash Flow
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Net loss
-2,324,013
3,499,430
-1,597,632
-3,821,039
Depreciation expense
28,193
-19,004
10,624
36,143
Stock-based compensation expense
-
-
183
-251
Non-cash interest expense for notes payable
-
-
0
0
Amortization of right-of-use asset
22,204
-53,310
21,000
54,105
Write-off and impairment of property and equipment
0
-34,189
36,574
495
Deferred offering costs
-
-
101,170
0
Prepaid expenses and other current assets
-66,967
457,168
-171,727
-291,460
Other non-current assets
-4,571
29,457
-13,437
-13,093
Accounts payable
453,801
-10,007
52,345
-36,305
Accrued expenses and other current liabilities
248,921
11,972
33,119
223,387
Net cash used in operating activities
-1,499,356
3,009,505
-1,359,793
-3,238,912
Purchase of property and equipment
142,773
18,989
0
0
Proceeds from sale of property and equipment
0
3,675
-
-
Net cash used in investing activities
-142,773
-15,314
0
0
Repayment of notes payable
-
-
0
0
Proceeds from issuance of notes payable, net of discounts of 287,580
-
-
0
0
Proceeds from issuance of common stock and pre-funded warrants, gross
8,499,835
-3,721,692
0
3,846,692
Issuance costs related to issuance of common stock
477,592
-
0
464,670
Proceeds from exercise of prefunded warrants
85
147
0
-
Payment of finance lease
1,070
-1,943
1,015
1,979
Net cash provided by financing activities
7,556,588
-3,254,932
-1,015
3,380,043
Increase in cash and cash equivalents
5,914,459
-260,741
-1,360,808
141,131
Cash and cash equivalents, beginning of period
3,082,268
3,082,268
4,301,945
-
Cash and cash equivalents, end of period
9,598,916
3,684,457
3,082,268
-
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock and...$8,499,835 (120.96%↑ Y/Y)Proceeds from exercise ofprefunded warrants$85 Net cash provided byfinancing activities$7,556,588 (123.56%↑ Y/Y)Canceled cashflow$943,332 Increase in cash and cashequivalents$5,914,459 (4090.76%↑ Y/Y)Canceled cashflow$1,642,129 Issuance costs related toissuance of common stock$477,592 (2.78%↑ Y/Y)something is missing-$464,670 Payment of finance lease$1,070 (-45.93%↓ Y/Y)Accounts payable$453,801 (1349.97%↑ Y/Y)Accrued expenses andother current...$248,921 (11.43%↑ Y/Y)Prepaid expenses andother current assets-$66,967 (77.02%↑ Y/Y)Depreciation expense$28,193 (-22.00%↓ Y/Y)Amortization of right-of-useasset$22,204 (-58.96%↓ Y/Y)Other non-currentassets-$4,571 (65.09%↑ Y/Y)Net cash used inoperating activities-$1,499,356 (53.71%↑ Y/Y)Net cash used ininvesting activities-$142,773 Canceled cashflow$824,657 Net loss-$2,324,013 (39.18%↑ Y/Y)Purchase of property andequipment$142,773

Bluejay Diagnostics, Inc. (BJDX)

Bluejay Diagnostics, Inc. (BJDX)